Skip to main content
InflaRx N.V. logo

InflaRx N.V. — Investor Relations & Filings

Ticker · IFRX ISIN · NL0012661870 LEI · 391200708PAUDLQ31581 US Professional, scientific and technical activities
Filings indexed 265 across all filing types
Latest filing 2023-07-12 Regulatory Filings
Country NL Netherlands
Listing US IFRX

About InflaRx N.V.

https://www.inflarx.de/

InflaRx N.V. is a clinical-stage biopharmaceutical company that develops anti-inflammatory therapeutics. The company focuses on applying its proprietary technology to discover and develop inhibitors of the complement activation factor C5a and its receptor, C5aR. This approach targets the C5a/C5aR signaling pathway to treat life-threatening and debilitating inflammatory diseases with high unmet medical needs. Its lead product, vilobelimab (GOHIBIC), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for the treatment of critically ill, hospitalized adult COVID-19 patients under specific conditions. InflaRx's pipeline aims to develop first-in-class agents for various inflammatory conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-07-12 English
Regulatory Filings 2023
Regulatory Filings
2023-07-07 English
Regulatory Filings 2023
Regulatory Filings
2023-07-06 English
F-3
Regulatory Filings
2023-06-30 English
FORM 6-K
Regulatory Filings
2023-06-28 English
6-K
Regulatory Filings
2023-06-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.